<DOC>
	<DOCNO>NCT02772367</DOCNO>
	<brief_summary>The purpose study investigate whether cell biopsy take patient skin transform cardiomyocytes change cardiomyocyte ( heart muscle cell ) grow special culture medium outside body . The structure function cell study determine patient breast cancer treat chemotherapy include anthracycline ( e.g . Doxorubicin ) anti-HER2 therapy ( e.g . Herceptin ) develop decreased heart function .</brief_summary>
	<brief_title>Generation Heart Muscle Cells From Skin Cells Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female Age great 18 year Willing participate protocol procedure sign informed consent History nonmetastatic HER2 positive breast cancer Prior/current treatment anthracycline base chemotherapy follow antiHER2 direct therapy Subjects cardiotoxicity group ( TOX ) must meet following criterion : Prior confirm diagnosis symptomatic cardiotoxicity associate anthracycline antiHER2 base therapy , define decrease LVEF &gt; 10 % baseline &lt; 55 % symptom heart failure ( NYHA class IIIV ) . Subjects cardiotoxicity group ( NOTOX ) must meet following criterion : Completion plan anthracycline antiHER2 therapy No symptom heart failure ( NYHA class IIIV ) end anthracycline antiHER2 therapy Normal LVEF &gt; 55 % assessment end trastuzumab therapy . Maximum absolute decrease LVEF &lt; 5 % baseline end trastuzumab therapy . LVEF assessment perform baseline least two time point trastuzumab therapy . Unwilling unable give skin biopsy Contraindications punch biopsy include limited bleeding diathesis , determine investigator . Known pre‚Äêexisting CV disease prior initiation breast cancer therapy determine investigator , include Obstructive coronary artery disease ( stenosis &gt; 70 % ) Arrhythmia paroxysmal persistent atrial arrhythmia , sustain ventricular tachycardia ( &gt; 30 second ) , ventricular fibrillation , cardiac arrest Cardiomyopathy ( EF &lt; 55 % ) Heart failure ( NYHA class IIIV ) Valvular heart disease equal great moderate stenosis regurgitation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cardiotoxicity</keyword>
	<keyword>16-025</keyword>
</DOC>